Category: biotech

.AbbVie has come back to the resource of its own antipsychotic goliath Vraylar looking for another blockbuster, paying out $25 million beforehand to create a

.Just a handful of quick full weeks after succeeding an FDA Fast lane tag for its own investigational BTK degrader in particular blood stream cancers

.On the exact same time that some Parkinson’s health condition medications are being cast doubt on, AbbVie has revealed that its own late-stage monotherapy prospect

.AstraZeneca has used expert system to devise an unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to separate the antibody-drug conjugate (ADC) coming

.Monopar Rehabs is actually recovering a drug from the dump of AstraZeneca’s rare health condition pipeline. It has accredited ALXN-1840, a prospect for the procedure